The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see ...

Star hopes its drug, which is currently in late-stage testing, might prove a more convenient, longer-lasting alternative to ...

The deal hands Genmab a drug that showed the potential in earlier testing to extend survival in head and neck cancer when ...

Anticipated late-stage results in the skin disease hidradenitis suppurativa were described by analysts as “disappointing” and ...

Walmsley, who helped push GSK to focus more exclusively on specialty medicines and oncology, will be succeeded by commercial ...

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...

A recent report from Back Bay Life Science Advisors shows a surge in testing of, and investment in, multifunctional ...

After reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling ...

The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there ...